Drug-drug Interactions In Pharmaceutical Development by Binghe WangDrug-drug Interactions In Pharmaceutical Development by Binghe Wang

Drug-drug Interactions In Pharmaceutical Development

byBinghe WangEditorAlbert P. Li

Hardcover | November 12, 2007

Pricing and Purchase Info

$134.35 online 
$139.14 list price
Earn 672 plum® points

Ships within 1-3 weeks

Ships free on orders over $25

Not available in stores


Drug-Drug Interactions in Pharmaceutical Development comprehensively reviews the relevant science, industrial practice, and regulatory agency positions on drug-drug interactions. It focuses on the evaluation of potential drug-drug interactions, allowing researchers to address risk factors before a drug is put to market. The book covers both clinical and nonclinical aspects for understanding drug-drug interactions as well as in vitro and in vivo studies for use in studying interactions at the drug discovery stage.
Albert P. Li is the President and CEO of In Vitro ADMET Laboratories, LLC (www.invitroadmet.com), and Advanced Pharmaceutical Sciences, Inc. (www.apsciences.com), and the cofounder, Chairman, and CSO of the ADMET Group (www.admetgroup.com). Dr. Li has over twenty-five years in the drug development industry, is a distinguished internati...
Drug Delivery: Principles and Applications
Drug Delivery: Principles and Applications

by Binghe Wang


Available for download

Not available in stores

Shop this author
Title:Drug-drug Interactions In Pharmaceutical DevelopmentFormat:HardcoverDimensions:244 pages, 9.5 × 6.4 × 0.85 inPublished:November 12, 2007Publisher:WileyLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:0471794414

ISBN - 13:9780471794417

Look for similar items by category:

Customer Reviews of Drug-drug Interactions In Pharmaceutical Development


Read from the Book

%PDF-1.3 % 1 0 obj > stream HT=o w~:qbKCE5iw gRv > endobj 3 0 obj > stream HW???Gv0)R];vA?[-. ]z~NL6)u?^+}?OMz?tI3MydsWY|uxoaf?~U:Z(W.2$Uu.:I|dnjHn{]_Ec6JTmA?!;VlF6''bs|QssyAFp-U?dZ5`/OE_? 8R{?EYuUw(c??? ,?18b??j??;$2L,c%W ,2Z ?G yLq?Ms(YiyO[J~O,L?_UF J>pKJe/ #kF4qa+RX~$ !|?iO,%WS}I?Ky/$f.d,vXTP5iZtnn/c7tumj483Tfj=ú)?s!j3,D?/M9 Iid(Mu 6YD3?e RQ?^D''?Y)ZHBG>_9r I?irOWp_g( mLB?)W?G??LKl?\|6?Z,3sZU( Q`:B0Dr.EW) Q WVJC  hSdn`? %)zM]d''TD?sx=\OFMoU4a#ƒ u*V{H??{ZU5\qc=GI PD3b?BDS2 TFK1P5G) v^%0FM* a)7,a*e/S%!;ScUIb?v4W{!;Db]* i$j+0%5?=W )fFds?cGB4 # GDb#eH)& ?g^b~S VM[ p9x*?.B?tA{/?lpG(wCw+M0P"}[D}($( PiC?c:?LA0Ec.*V$?TY4iw(RjChjiJo{nNTp!j!Kqs& NF;yQ)9J?f~C{>cyk>w\HY4f2r /jnm3G5&H&4nV$c&%jv(y\ jwx"Tur.P??PhL A`0\Qd8Bmz r47 TDG(%[ ?? ?} i q*.?c{mE|h|IK3eg@b}[5`Ww.0{ wv8?$ _?`?p{m)8 [fm{BR%O?a5V%F\z Oa-?"| f?.FD*Ioa?p?;A? 5u?)e%?1vM1brc+ ?H$ J$*{Bo{vqK?73:lJ .Xot}S:?%`fr?nqDI /,j?H6mIn>- `? ''~:^R+(rq!A?;ho$@69u+a%yW6(@:ISex:OA&OC" &}?gavk_+c]n~_Ser4?&ZgS#`a(?E?|ms1?U+n h?NrIT8,lk+XIFb7n:V c5.Jq;) \V -a@? > stream HtWnWxXj|,''L x?("B9?,[hU}=Oq7rUf6I/.] OxF %,ToCk .QSuAea7} ?kEj3tQ''E.?L l?ijPS[Sr0Y-wRe0Zhe?aW{K?)4T)T4T`!l?0'', 3=WG:#UMML&:Jsdv XJ?PEiCC+joy#?mK, G\\= "dIS?^yHKs*Y!kdQQ)XoxERWC?? {?D *@rus !;n!c~(p6QgV ?,??[V-Q8n^@g4x?LAR d#,?D{SbTuGYTH^?(Yz,(pn5?m?r& z0V2?XFb\qyP4?nDOC>226:`H9^.6é?|4y&i}n|n'')##PV?cW7CI?vRyS)J{q xwgqzP2?Y@6''TGHck9zzY?BQ .?2 ?VM5?e8 1q:P\rJ?W? Or?.? >?|#6I6U `b+A@\NwJPIhwg4]ea.5Zs ?/ GCM !u3i8Ic*SM #?(6C?µv1_4d?O?]F?Jp V?V-aZ?ajc.na!3?#!I:?l SkD?PXK4]Kj\?1 RvUDESntHK5W}hIL, 5)X`TsKTQo6fSb/-  (c]n z^,q,e1CV|?8dr?o Þ`m&S D)A~P)|kt{a''z$ 5jk#y///v?/& DA:*:S?- > endobj 6 0 obj > endobj 7 0 obj > endobj 8 0 obj > stream Hbd`ad`ddqvwvL) 0q6q5gyK@H?iS?|W7oV?yEowr?[>G N7QjZ?zV9H''iW%CT?F3nfigoUD? Y:6M?m?zXm0Xg endstream endobj 9 0 obj > stream HWr+Mo(LeUD*bgJ~7}{VSf==}9}?oKuy(9s?*_^\d/A]JT/?*0O+c${}mjl$~~z6=t''7MY(_a6ÑBd"uf.o?~r?Kfci8x]1g]1+wh?a;0?:?m?r*|Y!\g]{W_|Mn?X~UK,$}M7?O?#)7BUy|?OM ]} |@?wfV]} ?O0+6 n[K3r6@QeYv7\$%I;2?YyiJf*fRRwL%|}{dj#)22b?fk =dGIvZnki@J*B(EN? ?%KBk~-) 4Q%~>2???R&JE^?I^)p?Rew(BWt U`L2%D, )$DkG,= zRJxxLC [d]F"Zi-*Vd->}02?4nj\''!8)''Vp%">{su!Y:X3N9$?!i` )Dd[suN4(/.d?vt''Llfn"W(!?|Y04nD ?X-?\x~|(&=s9T#eYtMq\z.4nb:a} Y_:A e?.?5?}|PPEW4N0RS8[}!Ey5ylQ-Y:r+@%YN[e\!B,KcT?ala,g8Ng(>uVU 8 d8$va D?~YOsƒ"J#?P b*H+"AEKyS?Ts[\&?8|sy''!MU9+`ue?PB1nR|dJ\0ch?OD#OFQ?*s.W qG-] C(bTNtGçi? jaa)I?N''Y;"K15-M$ YUMK]i[[IlQI&_D=bJT\*j (.1??? {l+NuMLUbs> F9+S@V?fJ&z%w?WqC5Zdv9E`^e, ; D4w=No2Pw9ogvqq-qD!m:\jF >TNFi~Ovp d]V&1mW +?]; BHZ! Q''''Hy f!~l?yiLJ.1Z+hll$A `?Z>-''U;s?\^CbJ k9 ?nNT Nou p`qK>(iV&r1?.YVV ?ZmM endstream endobj 10 0 obj > stream HWn @Wv8 %q!$G;SPVvuw]Nzx^"!3J?&5 +_q? xnz?OtS}yri|uNjZy(j;: E]VyR-sd{nwe3o=W4$Jn#vyIS?T=~TwrC,a?C/NSv=[CO{Q!5?/Ev;a?R?U+p )XE~j y/Oi0]giW(rI?" gR09,c/M4Gl"}TrgER}yGoE?XW!N4tM=xA#~?%eK29D@HMGF?#` yC8v?U?SXH/ 5?B0M"[h\D2|;*y1O# N`VyX?VgC3""2t{`:?=Qor3U!O Lda_ QPU e+z9]cgRpK:t=?0&?\E"2-#?)q''hvMIQNI$z! =]|0`$nbH9,T@?L57?N~i"6M??^bP?vX1#LK^2t}SVrodLX%9 !_ZG|6%eI|bbL):,CJrYW%6"`Ý4}DG9QM [0$tbQ%O(-ajq?.s?L3!C81MU''(?4f,1G"o-dCY7MJD*=bUBOn(+aLGs!c kOJ{n.L}:yDQ_USrD?-_58K?qq?N3uw46V0j^d0) u2_o[yJ&[5OYm=X]r_ 99 E{ ]e4 [NX3gUU0TLYz#K7]HP2c,MU#p ?[A^*6RstN??Xz rf1lY7*&}iK ?@j5)Rq)?ekii;Z|s0Pn8jf°JL I`sO9 ,?C=? @z4HfE[CDChÄFEo"!N&o7eR"?G$(|9,a1TuwdX2n? CDEz--y2 y?I~?:}S5(pi?ii?+''9p?^]Pcr=Y??` w(_xM~ueam V#1GdJc5geF[A92&mNAOShUHt33N|"alV1 kyYE3nf"?cZ?MC^&]]_3~(5E E?-lB3IQ)~.c&+?iNGS@7Ft+*#Q2awtS/4˜BBxWh[5E8oZeVkReVQEl9>kT27 ??uY4Q7L.j}P~i?,|:7e ?dB`8OK TQ''6}& 9/B`B9-(rUYv`x''pY2lb2.B?Qqfv] BRQR=7(/?xMBGme[p}aU$O,=Ti=nk^zeou''2#HZzQ/?G^xQQ&O_ 4#~l%8Ahp > stream HW[oF_# = ^x?\[8n( 7,aYIs=sLlHgtg5rIsRd?E?/S;eiuh\9}n 6J3gZ"gB`BD+YP:u3 #NH+@?3gJ}Gv=RR(M|C }Zg]+gp}duUoA=*7mr/LO1|G+fb?0nC?6#\F2E?D?)ar*JO-F +p^]?>8dsI&ee^S!tNV g-^o7 bR8)n''?pN''8`NMO?vD P3ip2?}l:V8a!|L N m}?2vPo!z >g ?OwxiZF?A"z&7w!H[_Fh? |[QqzF?)x })?W"nFQ^=Ta$;p''ZG#|`mß)XuH~/+~ 64BW-dkifJ8,%c}27B+I}|^:9u?.IM1GLa?{DB0/ Owp!46W?i|;)e{gz) [ k GvY2OtFlNr>Gii?oKWV08?p d!n&[eD_w3&=;4Q¡|_$2C~cO%tY$YS&D 7lZu|N}?jd8,-Zf}?ŸwlPxlS8eqB&B%&oM~}{5fjzo^>=?t*C 9nV??T%(g?a?OMW \qw>\ =thWz` S5ot iA+Mv6{; mmM 3$o? A&?)1!f>?AUi8iT70h7/#?Gh8+u0w?}EZs}?.J346?g9c TC:HsAN (tg[Es?b|b@uuXMY7s ?W9~YlCqE@??Vh [ g:DR *Y.:,G ,lY:K`)FJF#Lw > endobj 13 0 obj > endobj 14 0 obj > stream HtT{Tf~¢ct5Z|D1"AcAT c?)y8~?kO=?+n^9[''%%%w *ezCWW*;n8"#Wi-,Q zF]q$d?V$''2 TR)?XF+! kQ6VzWHeB`gQa1(#C`3?th^W\o?BV3;L.|u[upR&d Ljh h= H`pzl9Mm@ t;T \?Dt/Cz>:ßww1)NrvfqYeS7xM, ).A?pX}hkM5U?=s)o?] t?|~?|;0jvT5X[`g+KF|{.]Sy=%H#\\`acJk jj5K@1R?>3%6? i6^?Z?mvyu`th0Q`lv d:_."!7[hh`?r6m ab3"69l:HRfWu*4tWm "''Y??qBy|t?, Wi4Vj?e5,?mjT&fc6YLPa#"\7r,;8atlL!t)8PJ0d ??N2~0rp bM8`w`?(?,\:zo,SSpT8cE`AAA?& G1 ~;a-,D8&>q"`''G: OP*3 0agixí!Wdv?S6?A9yJ(~6?{ w2jLJ QO#`,qv/Fer8}6 pIlh@U?G?-3wLc?KD$TK?di^-I*? o9^|s 6@6~hT? b e=Uaz8/E]/u~av:?L>:b?l:UQV$x:-#f H )W+lzY?#jf ,Opgddz|$b/=vc;#l`8~DMUFm:#UXbr4,s$72:J ?k*Ef#`$|&+!\ R5V?aix/)?>g??%sLO g;SGp? V>X+D-"WY?^q+Nd=MvDr!>DK?Cll_A\s.U+_(41Uz?x)ms~¯ u7''R?,n Iip,~BV xX!PqQ`o1:_y.(=eLx^:i''xOUd`fyYP&?!>yD@MlT8M!j,b»8FQ&@J^w8#*}?s..,{IoeTv`AgqVd_DEBahAGDl)vi?/w?pn}vePhH"???=?Mtyp+cPFb``]~}M??lnev]b/j 8lQ _(I{`t3>i?vsd[b%m>@vlCu:Gx@nx*.>M?U+0 M E09I>0Xx-lKxT hBZi1y$,*9Y ot ,t$#2  }& HzX_hl(0e)\NE?\c@''GSL(-g`Uq;9C.+qCF}^?c`.$@5{TmR0C: :\|Q5h \  ]kKU?!yFdktJ -y endstream endobj 15 0 obj > endobj 16 0 obj > endobj 17 0 obj > stream HWr}W%U`b0Sy^%?lyg]\X(~? )r\e =}9}bv[5QDf?aL5?: ''g?S{ N8 ?1vkUC 2{#Bk\k{?lR^J CR\PfA:ZlZ RGpFNpQKo{[\?C )!Q I*Fr62X?Y@Lk ünHRZ"?/V|^$}cRpby^,z_,]E PHpx F9en9~$ ,C'' r{=Î/>*wy4 "w~lS?7+~,V+9ZW/m-dl1uaQM?&V''7y~w?uI;LS09?2I6RA\GI ?h PT?? $k g8l2$gjYE_ j1y+ f?o+THD'' iNDojZ2?D H?,$b%r!Qyfd>JkQV7t0({ %;m7Q o4QUhguH?X?PK?!iq??x?[?S}+D#SOri72 _E=DÇ~ ju?_''2 d+UAWe?fb4m(k1(yu=y6%-p}hq_e0 Oc{P44P=;ML,x/|W > endobj 19 0 obj > endobj 20 0 obj > endobj 21 0 obj > stream H endstream endobj 22 0 obj > stream H,KN0 JR8/ l!u?N ( !|= `2&?O>8oG;19onm'' x> ILc? (RtE?5o t*t #2?i-[. & 23o4|T~S O4HBbaO@m endstream endobj 23 0 obj > endobj 24 0 obj > endobj 25 0 obj > stream HWMDqTTY KX%p?>\a^H^ .o^|{/pimd9OO F)0F_nS!Hrfb"Tjk&lSd &+6N5~l?b?oD$ VEGVDV-ym^~m(e?Tp+u=Vbo CQ.MI)vk-yp[94?+ ?ST?i?W5MwBcc_ã''?S];|? 9W~;3Rc?Oku>[7e\2q}WO .Id S_Y_&-WxIg0wy.y&T5qD[In0,r c|E@i|Si1c3v"K?vazB2.$ul-1b/?];4''?d0?;+HB? aj?wxo?A. ib\ffL9w 11O @ã iluA-SR9fI endstream endobj 26 0 obj > endobj 27 0 obj > endobj 28 0 obj > endobj 29 0 obj > stream H|Wr8+tD$HNe;4q9@$aL.rYwA~xR8* ?? 8ONL6sSc 2evc*$ %FoB0%cSmAf B*Jy?Gs#w+''r"rulHws5?)FT i?~ Q zH5nN\~(w?v:n?;lM>uZ2B:V?W sF\?tcH8>X1K?/tE?x=egnG?AK1g*{su2kW`vr3i[d?fg wI b9?}Et > endobj 31 0 obj > endobj 32 0 obj > endobj 33 0 obj > stream HWnH}W|L.bcE R~>j3xBN?.I\UvX%Y xxj.P>?4tpO f#nw,;^ ,0Hm`/)? A%EpWR!J:[2O*)e1|nD@T+$~'' d%"l? 9/?,R1+Z}2|r''n42x jx{3ot?"?c+:R" ?\ifR4y,s>u?=([?  VeYlA7u^n? *g%HC[ > /ExtGState > >> endobj 35 0 obj > stream HW]8''h^ F Eq 5"]|xzi?/?n70^.CU..[$W%-tJþ_*4IyN mwioq. cm(?wX| rYUU[2q?%bjZK-r }w)C!OBt@Wvm}i 1K&$O- ?T2 c=6zi? P g]7?7}?2eS-@aS{dNrdpL3N |@o?nRc)#K??3Z}0 @s$YdfgXld''0/Y=3T}-HA5aBT-> ]o=??0j R2x~_R:aAjPPf?T|J^JNBN-t?a#9a.\}t!4B?M%D+|b[i!$%-h"GBguIK7Z4~5qjN%_?l F\r yKf7W?qbn*?0O /pXK=1@CAUL1k=?s\>3LcG) ?`SKgq s(OgÝ!&cmq%" ?r8Aya0Fm4 %E\5{U\7ho8mJ,j n?#a4B*ALEe?''O?0? TY01,eGx˜}#"~=0P@2Y)`O )p$`5U@s?.''g96a.PGGRE\|l9CALx?m?6G 9?yaEj~5{0 zzrH HuM 8QAhO{ R,;r? JF''33J04Z?o\wq>McR+H""bR!:4qSYzU[)ZPb?dP/KdDa?T;!%A b.I@4UsH(a)E^e e%Iq&?4Z[,V[7qTH+ gI0ez2?_0kH#FQ\;> ''5''(Ln#;_3:7wTd%K=m?Q? Ö9~ ?/8vureK =nq>5f (?|j-]J?|/YIO?pv*C_Hi3Kv| X/bS!,gT8^33H sb?&u+2IF5?&1u[tv)N[/??rzx]?L su?[z.owm? BHDj*!J ?u\gy;IsWP6s8}z? x8k?*o{+3fbP{+&ziY,Eog2@c"DkE\n"??Ps rSD22RYg1cr:% m x2Mj_NK41''?,#t ?h?"c$Vp^Bi;K"[-U,?l$; xy/?zwXexU)j =P*S Z6-C>h %`j/ :e endstream endobj 36 0 obj > endobj 37 0 obj > stream HW]S Z?E4"oAhS?,T1;?3y&BohEF(.t~Z9%=FAq +UQXdO zn7z1f8`i "z Jh__C''8#?NoXP)/v''?pAtR:j{pE`#rc?onQ 0?^3@o}|zdz3bO:g$o 4ÁCLP>m5 aB5|tqDR4ipmTN\ _),s!F9)u3m1{:}U6jt~?*0,^C %t(0J)/S?3flM  Gr ?;[ED{xJ`?raMa1!PFo8eG(u=; 0ssco.Mkgx 0HDO?>M`0I?hx% 0m^W "YD?W3.;j9Tc-D BD a??t3v$"V?4e?pf]?:D31F5b1]%K)^s?mJ\?RMPh?#!m;?YiiMx9/9~/.(''(VcC?o 89''j?bWl?sQU3zPnega,$m~4mka/?FlqSp"pK5am g*cuaD!9j(x?8 $G?Wr¾^)?/,#sn Ud/v>]|e2~?%>!Z+d#j"d?(??8x_!:Go1?K0X.F.PYl_~''>E_P $o;KQ}_? d-L> d3i;7i]=Xg \f'' ?^m| @[''?dXmU=SI1UQ7k\E4J ~ ?9Gx[1?XMq2f?2Ml*,: 7'' kLi5-D?14RaqQpzXc- ôieIR > stream HtUiPTg} 5 4jayOe1}aQkE "eY[h,M@PAv"qcc?e*Sd?s1*c~Ws9 ;Xr `wh4)J2j!zM{5JC *u!V(uGgUq8#a"L:}ytNxj\?98 8b@rd@KcQK?o!=?:r w.]OB+kXC:_PAKbJ?%8YxTy:$;,?4?j(Uf s??+7O/''}HIAB7?q^Qxe2jy$;lUn`1vH68T*E=C4A3iS,R?C2:mu~qr,H,xL? ~:uh!S# )G''0f:H&d ,"''06aJ5]1Ud7RB8l?7B8VpOAT,b!rCcr :ecP8xiML:6viy]86Wi| w?e`(lk ,F?3&t''\c]>MP{{?0wzaN%V5zl?~^=eWtLeu.# e )U\?qwÎe t /si{+2m Zld3ew=*,O GN.?rzF6|¾GM:[cJq\W375 KRW}3aZ[o?md0 ?|Pl*3X?9DJ~JM?Z@&uf*x"p.8WN*\^D|o9JRs~IK-n;Xx H{}mU''hLCG)aV5@!-S*Yc }8uCd:?SyAv4"B? ,]r>Dtw5a \noM.zDqF ?,z9''d?X?`kX8^rznNZVnNgr zZT[` H?3ZA?(oLNLcTNBi>kWYSa7tV XUk17?^U ~MjjBK:NFQ;=S(,''WY)V`Z^i endstream endobj 39 0 obj > stream HT=o w~o22Y,*yhSIwgt?}X:pý?u?1%B? -L:p ?\{ /dawqB@R`q`?x5"45`q i?"G 5 > stream HW[oH~?X8>Q)UT@R605K+Us uU6s9`Woh ?z.3xz4b0_umKx^&P?: #I`tGF&`?~L+w|2YN ?*D2WÉ:IYuQo2p5PaA4T5h.H!.9x b6M0sK`6Nb\T ;CJO)d'':&L$%#=kwR e*6dl#L>O%BFW^:U`|OtbV 5?u6|8pZ=$*''Q''fCAA^W;,2IjLaqUR?RL A/:TSrH2q?* n5p$#ka{?7? wrâC?yZ E lu5U#BY C@%aoB\ls{aDA|(:2O!1+:t7GEhrZYa[Gd1?- ]CI\kY+V#? Zhmy~A8Apn]?.yx5]z6?LwW&} V?t>S\` ,MSp endstream endobj 41 0 obj > /ExtGState > >> endobj 42 0 obj > stream HWMW? F4/8. A%fKBR3/?i&z7^?U-2?L0WR???^?nf_X?>?bgYZ$]0yjqp?U?i;?06uI3 arHQVI/ ?M|NwNo_K$ VF?%5OpX7J>XtK0s4fY=Åm?_,*z?J?EA?> W}hNYDC;qm5QMKD#E.KOFyZqE+Kxe Ac;sj_u2ºu-Hq%1W #/yqazVC!?YXV[UW7a\j6d Z"vmxv.s,]E} X?v/?F^=`67 V?q04;JYrU^A. lmoÜ$9\1T5u#k|?5q+M``Dxflem(aa_=&pSJK7opk S#Pt_Ff&RoDx+H(>?|T/:1?X^wC?%o`% ?3x u4Cl4"1 R ?F-}\M T?KdfafGG*"nx? O23\/I,OmvkW ~cs%TH:C23uUq\9Ov?V?gx` H;v_Q$|G|a0_ S ?7F7 N?E6E- ?EQ2d ?''zj{R+4(¨^z ?e/8q =GA9K''T^du;Fs(''??+`XwL@X-qF7X65S&0\+GZz}z/n;r#''LaV?QGSU+&%15Y4UL: G%c^7g>SkwIJ*]wcZF(g@^1t@9&ZpqEQb2w2,Xe?9G73?r?KlD&mB;?10K ]v ~EmA?G)DH`%.U |G?m ozvn;s Wj]0(*$|RoPE![A}l7R{ ?b@"4?NFc ,`z!%]a"( };n5SfC qq ocmSKOK ?*; vLlBd\d:IQ93DKh[*\,;]sRMB^m+o°aMiumT9>?pnKU$W $}B^~aASgN?S@a?h[l+9("o0!cd?/GJ/ y)~eE ?nh6xaq5? > stream HWr8)|dOIq?)[U[S3{)D"D nR''V)W h?/^ti9E7, c#fvhy?xy~ZZ/ ?n?hjNKB]?}3 c?+?\#% //x6W^o\_|;x?m7b"b?r&&GI GYr}I?  eMf:e?e[KS2?& h}s?U?C2f|hJ9lq%P--T#K k dd6:&SSg&z`,c\i.o:5|&|N=CihEX9/NLpC$hsqo?}-exxFW Zo?R RkzuLmXIW??.s??F4?n;m@*3X(]M,gR$q}?- Lx$s>./g:=>5_a#G;qpjHQ>s [{_|B up2?DuH9$hXAGjb?@;IL+>zR:2:2}%J{I?QB?h??i2FjmDXnÐTRO*B*x%n,V?r$?oX1>m?Fp[\YfKY;QBGCx??Me-Bt-db[/ŒnT`''M?3?SPG?0pK7zR XnU ?4~k! > endobj 45 0 obj > endobj 46 0 obj > endobj 47 0 obj > stream HW?}W?h?D?2 -63^~Sdt?`n\,V:u{/;,i?O#?0x\W!i3a~F 8 2yRq?"i#V`?l?w0hF »5}F>45S;8E@''EMv}HK:6O>Di?Xwytmg vN(*UdbHY.5)_ ''b[ 8bpYG+JS?!&BA{%^7IWne(T-7u-^til=?Gq?!d ABiX) LVz~ZgvLN?>Q& )0w$^4 >,KkD]`4TY/NpJ0x$k?gL)dDELo RJvbKI#lg(K(?j1Z>:A2@VY-1y_wcPp ?zY`38Q#JF K)O@]?p7b3YgT8m%''Nai+1?dP?|q /xW/_fDzToOwuDSUY ??N``Wvvdl*)>~>7]I-:P{MF!=vUyjAE2?5&2N ?UeNPmh+QF 1 M }] Sp~J??N$&be4G+tuUj+$,y_?q:&4;m?#Ul A}f, Ds QnOh Wewy9@f$hcw? 33;/.h*BvIdyZM"T B?(13!TdKFjZq[:AED?>bw?x)}4Rv i O5& J/?n > /ExtGState > >> endobj 49 0 obj > /ExtGState > >> endobj 50 0 obj > stream HW?WhF2?0l!qln"y}p?G"6~n}7na?jU6_t+[U9.\X,?t/?_>$&l?KaWY?+ Sw7)?ZFhlC`\7?jx|PC}qS]^4I,vE5Lz R^O+U$olwT;gDZºBT oz:e?7t[ $K=]_g/Am~4>a d A22:K0ÿg ''0;Apq.L=slKH&g !~6-? yu8G$Syj>] =Hn?^f6)"80#(r3W7LeIK"X+ 8Ju:+/oi?q?RBn%?*C@~??Vy`B.|73?K~e&FN~#/C39a`?%=?1M{I41c)@s?o2 \36X{YJ 8~nHw8J33lF2Jg?^~q\ v5,UnX\ o9l_,TRY_|KÐ12vh?x?Q/B6(/*:U t tbl8:u$a+I_0o^6JbfxD2t9 #?q?i$]?0PraU/c\*A0j]ChK*M5sI%Ot-@eUN?1H`e??:rWrx>6 n12 C''i1)?fyU\g_-/idP:?? Xa;A/qG:|''E4| NKKkc l\T v%DL*,1n4m*iL/3pGt0{16{!>"Pv/aEn Av"? N#pH@rL F"i x2 r???P_yKhwv D!`9p$FkP?0~!Eg #!-kg7$!f? JAHskoh8''e~+Ud`Ksx=j_ssQr&"Y6 f .ie*^QrHA1l?`+lgTgAeaWgb+v!r>7oS[C1(aFfFYaF11U Ue$mdV_9.B6VDU1[Y ( ? P?QKf ÏAo h2#:UP@OMT XI*.NP}LfcOaz2_yiE? (U_\;Z&XDNRuShrYioCsq/+g8#8qq?K,?9l{f?oTS4$|D6p*&}s84lt?e?`A ?hvYX#iT0F$%?.?v?#TP ?J?RqA.P0nO ]d|)uy0>EiS]y( @m@µGrr`B^La GXp>S,):deDI- endstream endobj 51 0 obj > stream H|WNJ? ?dA$.0?^BS? Q y}7[T^osHzmL.mJw( 8w+:?\J?)?1q?y_]?g@&??Chnc6?MQ6}m:?Le[]?+?i]v[#hw=/[e C8LNOJy@I?O9u^[?LamIy_NU~G?muxf -sZ3Q6Sp"_[v (U1wQ#BA)ySx?z ["qNg"-!ek{?6µT^@EW5$j(xRd}3]Sg~z>ay§kaWM?Z"O]UR)PGONo+ ?^{??y[wtK.=?2?m+gS:3XgVKPnC9Lr[6 :r*bm]uGQ}3gEm]Fr?hJe(F*(J= RO1_D(lo+ ?ynw?mC,}6T;*O %7^ZD,x1-=?nJ??=''|U% >o^.e!nf{5 ?"z>aDM?P(G?~>.+8^PM?4X?uQ-CX??W7?],m*]>''IshQ!:+"?wy3z6`Jc %05e9bZ6k¨ \x bfYdo?Ij"CX&$% HYBFCeOI&_?QE]s9$bm4g E.ZhErH? ^`ce}5Dm?%Z?1Mg V}[92~G1]|r.G5QGYvE?aRG" X:=;ta{2_toX~U1j|!&f$x?p C*04?U $3"e?v~yhTCU7EcVm@l*f }!ntAqWpL%vB- m HH\"?@>e'' 6P?[H9zCf%..k?]0??e9BJf`?OK|,S?`x4} #.?!kcd5]ED??4j > stream H h Vl MQ`(F jK1 b2\^L6^yo??p(H4q "]uvz`,c|=?XNW)kj vm\S#bC&3zl N\,''0V+$}>xVQIVY/?IN_+;YB_PFRQNDÐIfY(x!DIYO}L?D1]WJr5Tn{RvkW"Z/TRQz>fUR"I''4! NI??&2;?f*ge!++N4wu5JGiaeZfyQkJYBV 8Ù+ 0x +*HV}U Q( FR(837qk`T"TK?Mh?>a ?hDdMY b0h /_ a?~pg&`Yh2)g9"bS Zl?JJ1BO)SaGYDn(CAq Q&nE h} q X?iz& Ybu Yp y&&8S''E?,&3%a" !&_46T;6?eYWGm???`n?M[ gsl2%?^_}m` EaH|w#}kX#\Es?(_d"}.K4 B\''lxQu5T ) ?M8#Xn rT4qK2C?V^gZ]%9/rCO(wA|k/kLO/J k*?Hay 7JR KD@4?a+bfx"y-_Y}wyZ7?r?fp /=tCtQO r*7uJM \Tj}4? 2[b?!-DMa+k^tu> _uX+?8>0Z?pY *HÊV?lp0F*)`?50. wj&J5 ngC?hrUd")K1 ^[''p?GUBD;*K;7reR$P|jE1}1;rH?|"''"73 %83cnYEEQ O1y4r"3odF? Ä8b¨O*[0E??@*:xlP X gA]5CPRB6&Svmm5  ,>gRou :u;s/?C)&}T6Ko0XoR?P2VO98(@}m=3dHŠ''R[pO_8a6S1dCh}RG2QCp0R#3b''=Ms2jXqxr\LU^%D-N)?3P$cW.Ovz+YaL>|z9xht}Go,\,????nyozo^o>{ P/B_z\LUX7y;9-Mi&0]a]wtk7?c?AAuTO9k8:JjF>#mj &,v5 u+>Dj?|~2+ *SwYOfL+~?n9`w 82& SH-,Wy2-[*14~>eK\TGaivJ|mW:dJ[ 7 g4Wž1OYM!$!?TO3|"TOg?J8V o:W+&RL`>(UÛ?;{[gkhnVê_?_M wAN|}qCqh6??)??udR3ZA#j/?q7kf0 8b''o:?a}ddT/.Y #Ò|&R=+9?XEIaWOWt%WiC2Ujs!!-"@`LL "&Lxj};$BH ^ YZ?=?PCP-yaLTZCv , FPt?''?+=+I~P*y -{75r=C?>V?5dp GAYp`*`S0OY.wI* ''?B`KH XF;;3==U~0kAb%d H1H@A?''?;W`]u= L g3sL1w$mZtUhI -s k$OsdHSm5~>Bm2eAJg_S|?K:!Epbags?$T `D(. H}\A?-^?1kdu[Abp0L_/3/)[N,WrQG?ju?u1UpPI!7q"7rbhT?tz:=6J+q|[# $-"O Y)Gh?#|?.y?LiR{ nQ}g[lGF.&.?eR\DuD?F??F8c/tUD#R3C+*v@?$7iO?%g] ??_)7v??RwZV*__5sEifoBRT^yg_c;n(7.@S[QE*Yj2  ?A!azB:?_S??}giiBi!jqYu~9=%|y.b\[==?3+@Qn ??&m] w9Tq 7.!=Nf|"$?T+RgZ 8s,{v[UW6E''?r|)S( R4 ?@+TaoDE?U|o5WlA@R$X;6lg~vm24 -GepYq%h?N!?a~ }/>vM!6`Be"g2*()h?u B CCNR(4.HaJfe1ZnA1 "|"/(C8hJd?l=NWTdi=t `b8L6#*!$O~42ZmPL@`aOFmTm]Y?~+''jk?jX? q>VD x^ 78c RWMM~+?TY(?~Qsp+i~*A qS9[I )??D{ Dn9X?H`?A2adHJ(h4 _Zf.fviW6wVorpN1dw99#?XW#ZFMzH)&^"8&qI*} .bxp zx[G;#=m)9H kzc[? Xq4D9r%`zRqMv-lJi? E?Xd ;M ${/uq()rF Rvr\Cr ;$o\o~ef H 9?YiC, ,O_}|f?>iV+}?J{Jg!. (N4 Y!X_G?o?Y?0R@1*M''ai^?lNtfk X[wztr8[~d ^n?O|Q;´,''y?|cM?*2qd0Cy%rA?0?sly~qJie} !M=(MUx dNu?|y}u}9ggRbBxSI.K:X}*.Q\#?#stsF?}??>82E ^2t2#:>wUT^RuJ|e9/;?=?8( ?_$?J. N?4J$ c?76(?`%?E!ª~+}oZv^`?>?[v??Jn=/]I?E(^ ]@ov D (Lno~FQ9a+`k1 }h 3 CzL3wK;?n!?m/$J21X2u?=vHB:8:Pik?~L3A i~0HO@SSi''PR.zi.?CiJszj}?+0D# W1^fx4?c9r7sB 7 0p''_\?@lA.T8][l}&}_$=Y2p xS-L)I` ?[IzRcTE8v?$# ?U&^^ T| "@)H/#T^c5i oJk{uUQ=2 4 K06WH\i2&(x1?#E@te"Y?QOB?8l\RK4?&^}gAA NO1$9B?B>46w*GC8&s FLHxB?qP i*O ]vmP*xg~0! ,l? }e''[F54=,?$gW?6._?!H?E" `49u}U_us$3Y$+A3: 3>{gG-MGW|fR5i!B@0/^avl#{u?b[Z'CYXmA/jdk''??q: JR^.*|f[D)|DQTPT:{^}J :G@GO?C_=9w-8 8z A?o@R,xQA*/u=]E.xLVo >F_ed''@?+>(6h)EN`AQ~rgOrmd&?z6f6JJk4UTmQ[?q)UX9$"LbOkP v?dy~5i\: 9lO+'''' dq? o,}?X?e$n`~L?(yggnkP:ld''NC>F?\cD GV%[J~|[3Ab CR? PdQQ@9?/NE :?O:f2\8D%N O\?q6Xy? \qV&]- ZYx 9q6:Hs/_EzjUeuVE?pQ6sDX9?l-Be$?;th^>7?Vz9n? NpVKjz])owQB{|tS8M Bw=7#$&"(>O o `0*~W]Q6.Ev@^1g?:S;6þ?>}u+$ ''O''.+tEdr??j^ ,bE_;!\_}$5uHt?yGZZwa.ssj.IRd6:}9CR[Zu /wr+I8U>>R;py?B`~^~u=?C1AYht;j+ GSYHLJ]r zB?Ka&[mm>?0J^0,7o~DuP1S@M''S&ZSi{I#B9?L~1rnZ$''i~Ph}X@ tS$ETp0/Inxiq?XIS-N?:"4\i6-`ma?Q,L9P8v/p7$ ##''rp n0o>1£q?125w( +`_X i26E c ?0?0[P ?)3/Rj ?ve8K6)r/¦0LX0P}m }"zdT`JG/s>?E:,L?hb{op&o^=]|gR]@ \B%8Nj45 L5s1dQ >BB48?{]S!lE6$#@0">r}KXEW$ iW(ã4A|?NID.fG?bom4XIGOGFU}sP???)tr{/?k0-DbA7^Eé-?Iw6{b-$_i ?QGq,?n {}dsAJlp2t[{sWE[X?22)3! _~a o?N{s8ZU~^:6 TzW?W EABbH$~OhnGai?[SMt?DXUKlZ?cunug^7o?5:k[w(lVmS8d('':N=3 jxg ensr%ucJn>2Q8v[fr9{C'' 3AWE?j;O0(,e^?E?@?FUc]R28?OUw^EZ$knaoP" 4>+[!D|-ens\YFk??sf]8p endstream endobj 53 0 obj > endobj 54 0 obj > /ExtGState > >> endobj 55 0 obj > /ExtGState > >> endobj 56 0 obj > stream HWn|?`?VÀ H y "/B''U??0_`R|O&Y6Sq_u|] ^&X+? dO?,>M}U" me:/F^C?.f//g ,+g_U;_?`@e2m?&=8\Wjr+=f gEa>~bh2,h! 1YEÈclW6?1W#u9]/%oH?qunYu{7s Nj8Lu"3?hY?'',!0` ;?U AR;C=S|Q`UuE om2OI ZfWN''m0C@Qa.x 8 SUUHVpL {r+js1g>4_!1Km?D10FaZOI^)2#;v{7vI  UFç?} `>?EnE7 w?w#W)1?h-Q{P"4?h[RC?~QY4fc PVYKP54n6l~oVy endstream endobj 57 0 obj > stream HWr+8L40\YkMvSe%/ ??.O5hZSlj?TuM!.wiN);m?>~?-?a!BAuESr''TatN?@vt?vF0qnd/7G=r)U \5Ztwk(0+?Y)Ri$rU [aK6i~"I XoB[/Wö;\* 5EsnM4$ZhaH&{9Vz XfnNAy`{?h}Sm0$/iXvN]{}a%w,K?0+?W,X ? X??2Y`?| +72D)riB B7[tz YCvL4I #Yk wL YKs-,Px `~n6f{syAgJ%^;C>0e2I?g41fA?Z+78Z"az"F e kb2PEL^|TgV3"3?f*7 vp=]ºFE#X6Y{|/>]?}8`2I}2a:j;Ij%FT@~ikWH_)oSs|@)3@??D(GP#zQNwnC(,FOx(9e \*z&!"jy]m;b]`l4[.TdXU-%4Oxv& ! m?4 7=Z>?Xvi*V4+ ?TK oF2[mV`??x dlxM Lgy&sS1''1?:oU~$&Ifu6H %`Z~Knw7_35K{l@TQL2dpx./B?P?G~~-u2y;Dahh#4Z3Vh qDkq?5 Z+?y> M fi0U3j+Z_U cdQ=e}n 7e&1IQ''?b~o ?\''Nu~p| ^ m^bEv7  ]7L|aT ;~>~i\%4% ?LK??;uV\!?y?C$_ rixZ;Pjn,kaKB^OT "(aMP_b''! y?QTRb>oUwd&%;R>?fwvz{h25AY2 3#rQ)cs8Oq|sMYg|r? z5ZI0''1zt?C+fW%M7?x).q+N)r[:DXE;O0Db\=?~sZg??){pNx endstream endobj 58 0 obj > endobj 59 0 obj > stream HL1N0@?@AT #0! Z&:pXmD6NkW{68??F-a?v|uo.c%vmL_]nat^.&Dr:j)Dy: ?4.#\FL &_}NI "$P@lXEy0Bq?Cg[?}I2d"Lu)MOo endstream endobj 60 0 obj > endobj 61 0 obj > /ExtGState > >> endobj 62 0 obj > endobj 63 0 obj > stream HWn}K* c2 `1%6tHO|rO"ug60`TuWu?Sx?{WE"fIqyl}^l%??|wE5 U7>46Q{7_-L{aBS?c\.^?y/C?`]cvA~?r;vC]2gU7uSG97HAj??md!qv}xY30m! [q8d-qpev *%d?IFSúWM?kFZD~;P?6Wbv|h5(!kWK-Mf6g^E4ct50{HIç?f)?LC3 zO({XO,m{$mTE8i`3G#gj1!KU7?HF=_dKN[?. g?dBw?/?t#v?@_jM8M~Gur$:L"j? 5Tv''^? P_zcYC8 gjG8??\]w e^nqz6Yt?># sX\|6? -R 90?A{?L %lT$_88pXiUDEv eY?2Ipxn;?m?3ZP~aFS } $0U21WDoX81A E5!ioDhA?3a?=)7f41gxiZ\8.W *,2P) 2F8|6nj|AB bH\=!Vl^R1Y_N\b gA|@3|.L__`F,[~?jJUW?4_(?;!9\u[ ~YFP$D2x ,t}-+y?:)k#nUC[&B]UjDK|oy EZ2CO-VM/KZYMUc>PD8%yET*&fHfQknO?0DPOk dQ>T]xp_$G&nltR^BGZ9L^FS? S@vI''NqH #jDJ{(Q?(}I{KH1AVAuD Gxi?C+^!pm%7?(24} ! N"? OpuB)jhDxp9Z(AQU Qn^6 7Tgi Y7;?XVn?_~j",I#HO4H?F#gzLym;? E_E4WC Fb8_TnG@K?c:Bnx Xb&R&#9 vHA:GduIB`AX-o$ ;V&|^=" endstream endobj 64 0 obj > stream HWMort @M`Ao`%EQ4H3{~?j?qxTw?Wyof?"-ei_ ,,Wy9T:-)mt6~Xf?MvN{ bpbahU)am Y Y~&uDotqialMvfqemkc ^1>3wQ// p]){J&cOMANg?G~iU?w^)PfyZZ uRo4w723jl*@8X$iSm Fb|-VTC(W YM/0y~vfl r"(XQ~ ,/,lc?SzvSt($RK,?@1B?a.o.H1+?iet=Vl -W^fxch_3t??V?9Bf?Ù ¬4]j$so2pjLOd.PGOr+]` 7 !WB rf]Sew.}SxBHOw??)0["= nV? +*~%K>>Ü"Lj},?RjOU 4?[?l^g{?&kM7O>7NBNhOH?Lp@jwTM~MB,Jp rv a6?;QG=njCH3eKK Kurs9]?,jz,0x c!}wUZj?E0 =mC)9pnl,WRbG? i|\Le|VPgÛ*!d($x$B}?~.?:M:7!ZWe ?:,?''eFHB]*K*nv[$E-V:s`~ ZP[w/!|\t''9S6Tx OW\?>W?(2?S]?Y87?t=QaokbXM~ .B16RkJ$9P?>SfN(L%@.TN9x5"23?O\Nt5Kb b(}w^u''??>* U:B)2QjW2BhpXE?1I5po>$!}''FKp|DJ?%,Qr|+J.]gQr^KD 4 ,(iY}dS@.M6f5)YIp3]B4)oz?cqS~gvFoH,\SY;.g. E:-^;x@W /`z? O ( 2 Th201N8.mjrT##Ft(*m6 vJ\aP?tyD> nPnc?q 6uF1ebjReL ?J?öy(0>fysw ''WXC{^vC|?~iTk koDHC=fH4MX=KTl(fH\b.cA?srolj&i6''[|?r`! P ?n > endobj 66 0 obj > endobj 67 0 obj > endobj 68 0 obj > endobj 69 0 obj > stream HW??T#R, ^&O7? HV/Y5VQ`.L,@Q''S,nO+^`37jGMRa??ak5iH&d6^N$_(88i=Y#(5]iTVZ(Z?@R5''sNy?,! z?&''6 ?r_.;bYc[= ?0q ?dF=Nb#K3fPdcp8Q?lN1Ì4{(p/>zg?U?de&xN ,#k(Z}7l?{ =P8 n|SD&Nq70 _ K 9UwDurd??) M`XOg9H?UM/]LI3TPhY`Od1Xc|>e u+J$c)m3EdB_n{ sIu[URXo3)4,n?cMT0[|AjGuGXkGyc"Ol:wltv''|G???p%XP(.NI]VRf|!|u^M?ShAB Um0hCp9¾?!t]l;Eh ` !S-A(?a;yUP($D6&/]1H)qR-zGF|L(.H!K`Ý`+Ua? Yk?m?:SJ^ NdtR*D"mJe!R=@q%1wT-vR ?;u/xupG}"3}(?j7 )^ZRNt -kM#j ;12? ''@Qo QHyX2>E 6?8?FWLh,y1:MH Akp!19lEj2-d*V3uYtm?: N7LAf@ S*`kI??O6e ?Rz` &/''d[4R?FR8XT!=ttz4A~>5S8EYr;S n3.xbH$Sf/Ak=i t i4}9?? 5~BJY3~eiU?)}HK''f@+ x >Fje6cOrm7JfQtT6XG~[ ? YHgP-?P76LN5[8F"Hj j?CAMms+ZA8 g~$xPflH# ]4 wh rEAZPD_yK Hv0BGROzk \?0?=7-tAG?l?Ømg|?Q3B-|Q#c k6ouH|g?&\Z{8)wq6 > stream H|W?}??T}I`{^yaJx79Hm,?SN2.3}Lo6.ElO>siC?/fET.m$.culmf41720}G??lsOV}J?Y C+weqU ih{+pNwnT\.8$:V\ D a?k1v(TfTC50UiY?- "Aox\]b=C4h]?k4ly\fPa?"cp.OsSIU0TM+?[B"BaQ"G>ed_} :Yk''m0?F,(J{c+Fb(@cfV4 S9z5fQXM}uhIaV gIn;$5TtJrT M ?9 A!?vOC`"AGiy|D0ZtcVn$zt>a5w61/QJHYw3{IzU3s;=K p? z 4D YR%RÊ??fUAfq7eE?%r}$_|h?Ry?oT J ;^q#wPI/tc?PwGUn`E dYfTeM#%8 1?!Kz> qV+IO5ruZ7v55!/,N^eL>T{Cb^y f''*aLy''F7iaarvC}9ig8 zìH^s"ywDQwT0p!i)PnXCn)?{,qT%RA^v?%W#kya)#~U|Biq!>][''}''e;pX 9@3:h(ev5" A o e[3mor 0/GW?_F.?!k?Rtqu@f B3W : .DCe??ay"{l&G L endstream endobj 71 0 obj > stream HWMoW l.n| _''1(Hx{?>lo6`LGuW?>G{>o?&>Kk[W?}$v3U?ÖW[il,7y\DS3N cuH3#B;Bz?f19!?.~%~,HS!zX1SVF]g]LeLR" XE0wf394H?"/"?0eOx@XdnXmfT? |#T,rW|NoAk31iJW3%cZ6L- 9+ |f?8$Lh}] ]dCL_^dq( 1Y=xX4)}&?$y*AI''X"GSJohU)Zoup",j%/Sj6s-042Vd6$S#[=??R?FWRj8p2A{?ZU?uE[)j|jU.)? No-(oR6% P M gx?N935R/u%??) J]Nl,` ?JF1b.f''Z-`*pj??lI9?it +[P wTWdUvoyw:uQeiHKVG1_%4/\[=pqmL} ?Z-/G!@p?|1=Py (e >?,yQyx X?5l;y5'2 nj$f~Y@Ng? E#v;;''w]Kfe?[JH ,so_I?4T7$g?a>j? k?SSk$>U+l2e:Is!#/C|cE%A h f/WZN ?O{qbIurjlpF\ ]M=òTM#Ag0\N"?6hY8?±^*??>[-9j ?@>\,b@^8Qv`?x^?&G@zr#gmNhZT4 :?0fN?g3c$CsB?][?& Sd8VN!?eRbw''$Jw/?^Zr?ig C\OkbmnC^YB)yrx2;,1B]=mRZfCB{'') Bb5R0L.Dpkd[#i>K^a$gZIH?*T4MM''0 a R2 WU8 \=''79?G {% zHEEJ^~gM?;P;eSv`3wo^SJh>A 4l4\w y$!TrPlY;?\.24?? ?kFY+uq]A)z:QQw W8}3fsDo^y(rHLfG3i`.L :fU(=*?>?| 8s r8J"f8?KwGu?+fU/>=N)I\o([f_ /?'' iWZ?IC  ?&.?J3gDH?wd^Yo:@ }c"U|A0Si??bW?,*$ n}?,qx7%oe9Xp]>K[u]x-OXvN ''Yw[X\ %Fy 8~j?V?{%uw?I@IiQ''U#6&Di]''?n$ *dn)9=O:icPE > /ExtGState > >> endobj 73 0 obj > stream HLKhQM2if$EAP!EIB4 _P\TI&c2 CfNL&"??Tw?''?v#gw>w0Y= u`?hhrk??!0!?i _TJ,''DBl(^1N5&2g+bXpPFN^o-[{?4};|#=S`BE]+1?9__HMyJ$+p|Ap5s*Q$9K-IjUeuZ;9-k?=[0We)?!z/QGDL* > endobj 75 0 obj > stream HTPn0 tm%Ey N+)}%I?$x?%@ f7,AY:]zTd$wplwPBp ?>-#dKl.5G4 ?AfxY gB2g/?wYy;3s4/%|?;R_!h endstream endobj 76 0 obj > /ExtGState > >> endobj 77 0 obj > endobj 78 0 obj > /ExtGState > >> endobj 79 0 obj > stream HWMW%@+Xqo?86T"?8R%)Mwy?fuu}z?{{UFe?e"MZiz:onXjw7 Dº0fX,m5X&6JieyjG* #?dG_?(F=5| TEdM8?Q B427f?F.[x_8SNé@ z+F[Aqna-?3+xDt\?7:"Z?;??F7 gf?mZiF b264"oZ5"O56*lqq??&I m?YTG-w? .OfwcCX 9$ ?QmjÄo"03 7`lFTrogM*LM&*>cwL''XO)-gz''Y>n_PXTRHY;S(H~5?I[LE|N@RE 4h#)P ?+a?J( D5 ){ff f?Y!WO4g9@7h4Mb%qMO6*6z?|ZZ0GOOpU(?3NN&U]Ue%q T3d ãd}I*6\X}wIxhã}]?5?Y"s ZMQo7\",V"u-buXvO]# j5*?_`W O)CS=zAh { @}1 6H0p& ]8Bryr )d''$Y`4=;}l.H(^sGH$zJ??;#=FQ}kp@?Bjgi{cJs?D ? &25Oa1=t?\Qb 9?m?qG''C5_@5>3f69~#55`3R*G/E_N-N x?#K>B^_q &^$r ??KR #-$^]otV$.e=A XXGdy9N+PeHxjBl-3Z?R ]Z ^`\lZ,xohJG Ev=(+iR~X`2=:lJ[w ve4G-;0)SKl? {?JC 4]U[2?%@Mh4#9\0 o:J]M?iQ?Rg=|Oj&Am2?V|F:je?Yd,=[_oR{ZR?rP''Jw"ox !~i?xN x+4cfh|?b3T3yO(U?xj?OrJH $?FR ;Nj/x`_ ''O15?t/~9/ V4ABjaw9e!oU6 C=:@2Kut?$Cnw)bH=>Rr??bD>74hOAO*Cf,,(?Uf)V1@v R~h r6Pw ;sm÷z%iv5 g*@ %Q~P(Apy)nJB5>?cCYF ~ m`{_?c?#3SHdb++2u_Waq.g\2H8BsTb>?-s|{Z0hv}^Rß''r&5Q*bG0 LN'' 1rF];l* > /ExtGState > >> endobj 81 0 obj > endobj 82 0 obj > endobj 83 0 obj > endobj 84 0 obj > endobj 85 0 obj > /ExtGState > >> endobj 86 0 obj > /ExtGState > >> endobj 87 0 obj > stream HtUiTE!B Qd?MGM@Dp 44M0(8C4QDgeF3#31''2yzT9?}~~%#LLf QY^j:4{R6`j[=.TBFX$*#eG!6D9F3?N%a_2oN6`bm?dt?YEj ?ZKR36cBervKU?5Z?."#O?I;v*H-8%p w^ ER@,?y&/8a MLbO~cx]\X2-9X008BJ?om>tk=;zZ9TN a,8C_AN"0 xBTmiTPV .*w }bXza#r1 ~:B*UeIRad?0o-!?e[l6HR-\9??Oe>\%,#v or3b_L{ sa§Cfg 7mu W)8q5D?U# QP?:Jg RuGG+s j?sBEeb z(ZGmy1)x[p|ucU!k\\7`I!.5b?+X>6p|vR?;Crk"hCsm[mI''\Em\H^nA*  vM& 0@++yzS NfO~!?,^Rsjm''_P z&`1?w(L4Uq)!%Mn 6i@]eÑc`AB#?>x,9MJ.OU m8$ h8 xZ"VLu0k9>)% ???E 0e Cx`b?)^JeE?UgyQpmhB+? ?SRI%&kK03Qt]B vhRy# 7_v#AMpO!!  6iw%#nAK?akN`I0CsDSIh1M[aF~B>rXXCkm? Bs`~?!c3 c*:Ysq$eVN}1_$2Z| Pp?ea1z?,j,b~F*:U. a_H o5af:J@.r((_kJ2?{~yG!? n??X3NIk[K? / {J#|?&+F?ig6psJ!p1 ?W Y?,FudY? 6HB44NJs?s>zNG??s}o:~eRXjU+y?f2ps!zA"^k ?l, _?W 4?*D) L?p,%S6Q)?)h ??{:deq{h`FLh?Ccd}&\~I*oc-G? G =R{~DjCvr,8i) {9~hIJP8 78D *^NeVpK]$?tIavuh,Y&DK D+3CO XbUp8 b]H[/ !9kjT J''~Gwp{"V!7?`h (CWwo}p7_\`/Tm?$I?>y2P  eTT1{$:&C!?C76,A;F nGF{IKeNqcRupLueA*SlC1 /` !R Q4$fjnt4wa/ ;_kYjbF/4.-Zj[?([~g:W?G/08X~ta)b2t|)  endstream endobj 88 0 obj > stream endstream endobj 89 0 obj > stream HTP=o @reh''e?kw&"d?!U0{av#zcc8%*G>*Yj8uN8uxOj)p8?WwhKM~ ''t *hho_ex?e o^(? NM1um?AX?8g?]''L%F_vRlfmm''+p endstream endobj 90 0 obj > endobj 91 0 obj > endobj 92 0 obj > /ExtGState > >> endobj 93 0 obj > endobj 94 0 obj > endobj 95 0 obj > endobj 96 0 obj > endobj 97 0 obj > endobj 98 0 obj > /ExtGState > >> endobj 99 0 obj > stream HtyPw{? t!j s|yt*9r[;m4?t'',d? } = iB.c_ 8?DeRJ9txvGzJbB{@owg_ojwcq0{ #Y#?^[[0aidax!OxH?@xW ~Gc`?anOX\i R_m4D8 I{VS#_mL. "gobK]gTpJf7l}h>!4MGo5s`}T@&1:h?hf3p%7?E@ K hx?.J>0=uAD) pk 7QqU j ]6ª{J%UL2`L~txXUq?w63x .?)??I[ZY? ! O1j-$? ?m4W 3_W3dm%wdy \Xv2?>Bk?~#=ZjFJJN{^"7 HQ2-$WpR}F (_XJql_?NWHMI!Id_P?#$-}W?)|!"Y^lpsHg?>Ch_ia=pIYFtUq#lm9g?KMdtee".~u|''UZaT*?^^\?9O?lhot$o? y\ Bh#(-jme ?bmT%?Ms?S\SA5W[jmmWS_?q_j?:[VyL4F}zhGEo ? ?oz-vH&vBP2_p|~i'':9$? F4e:kArt_oAVIn (vj6\WyTS{Xiyyo|oCgTtReg!I F}YDV+H?8im:e{=-~?* c*rPd''An#dL`B{ li Sn"G . l+.B[0?HH8R>Z>gf5u?-=mA$" 3 E1?-LSa3>`?`I"?bQ>PAH wvnNZqNaKf3V~({BKrx?$?gX9gPf =Z =??)lDBnPK:[?t3/M?kVr?k3$dY[k cM#5spW =L#4+a|el)|YplKEJPFY)pw?+Wv3+Yg?_ k{yv/3y3lqBlT84zgo#?$x"ceZ7?*íV en1/P?0 D_m''5?KÔ^%b. `jy6vN?LJJzf?*d,O ulw)xU?U?xk$ wu fv''%M+cZ?)fkF)c3c`\FGYs{dPm''f8HdVu/kT Neeix,}nmbe4!¢#HXC$ `o*z C7?>?HCZ7m[Q >Q%krcI6! HuG,?:;?t: `h#''5793hu9?9QP*/8=7C@F ;g $rGj;_?SE*?7vc 4tSh x7wE|Z"+8H8$x3N5WLk m l!S] endstream endobj 100 0 obj > endobj 101 0 obj > endobj 102 0 obj > endobj 103 0 obj > endobj 104 0 obj > /ExtGState > >> endobj 105 0 obj > /ExtGState > >> endobj 106 0 obj > endobj 107 0 obj > stream LBKDCF+AdvP7DA6 wd| AdvP7DA6BNts9kM`oWma5";WfxtqV??{m=MNXZadeLLf .m=1g u]HGh554>?I`JtIl??O]??{Ptp_^z endstream endobj 108 0 obj > endobj 109 0 obj > endobj 110 0 obj > /ExtGState > >> endobj 111 0 obj > endobj 112 0 obj > endobj 113 0 obj > endobj 114 0 obj > endobj 115 0 obj > endobj 116 0 obj > endobj 117 0 obj > endobj 118 0 obj > endobj 119 0 obj > stream H,R?4n5g3Kf iC&''Mn6N$y#? -6uT^\:U??_h~?O7_||?~8|T~|p lEQDNc?Cs?.KWzpNHHT)9S0kR(1S;B??3f oI;q(k3^? > endobj 121 0 obj > stream HTn0 w?d%EI:H! Z?tm? ?# ,6W?u&>TfDu8u4xhJ$sK?z Fp )B JšADvEhoq kQ${._?Jp,)cY$6 > endobj 123 0 obj > stream HWr#RzD37Zh?T28  bO /lU83?.E|pybGyo&|??>@?4 bn?4r"L U {K^-6gdC^WR''j?W:$?]?;2k ?#p]r;j? cCB+ mN,q?w FrbMy.@i=(p5''k0 Xe*H[:oLhur?2 RF?bJQvX@#6F@#g+a, `l Fpccfq,6UY?EhP! H? _a6 ''"}}@|D@5k-t[Ov??ZvPF%gm^D?"?CLe-Uq!^H/h?/ ie{(!V]\}-=s@V?oWehe(CMw->[Sx4\o?;o(????q>)h?wMq}?n*yX!u6y_OB T+KH i}AhQyf?)In}â-9p&Bh h?xB\ep},.Bhhd^edD 2I DF7O/5{#WWZ &= g?nE#r?qjVh4E;mQs#0_?t??K-%Lpzo vo K(_BX{xY o,:M endstream endobj 124 0 obj > endobj 125 0 obj > endobj 126 0 obj > endobj 127 0 obj > endobj 128 0 obj > endobj 129 0 obj > endobj 130 0 obj > endobj 131 0 obj > stream HWr-o\B}l%"A Pe~`{sN7F$`}qN??''4m ]7e.I Vy-? ?g|rY?\:6Fc[Wmg?C3tQ^? |M"F86aw1 by*, +dl-XiW]#''x>l?F5cxT>^\%C6=cs). XrGrI+1T s$aY!''BUKXP.AA0Q\kl E~L.zK)''.áia? +86oQ4I??#??Nd{8$\_PqKUP?\j}I%tvO#{''|-oZ|R?AR|?>I}TNq(e{???#GuLw 2TY"/C_3)KbbÓyI"7"x1I I"FEId8$bp(2]&;@d>Fr0ppW4)Z,gBttP?|Y:$PÀi z? z7&?/?7? .>|^CqG?w-bv^S`+ ^}ew,@zCX|x?|~?`h 1#c1Wfl nZx?UT''0n"W |^2Q|%H9%k|Qn/RV3 ?eODrT? w?gH>JOEjB=%PbcYppc~)i#$7C`#g?zQd?.$-9p-9CMaR(YA =Si0GP_pDZC?|2o>''W"6?}fV#/?rv$^%?iz3?^?B f?|y9; /1h"m9tI[,G q?{Y4 Mr(`,4w,R8v|Kl|(a=en/M,=p!njq"Ji?1@l09^`dXElBlOfkyvy?@*Ym ~9" .d/4>_W 1$EF "''{l54 7 ?N??g)K[??@??mSG+C*@ah@EgA?L%>t~ 5idB8_$RHfaYz}^DOof|T%&EL8{ > stream HW?} V4Jr .t7u& ZSNU_9\I?,K?Dk''E:x91WtfSXf[? xGW&&>''8y?CG[8S/{uc!W ?. KUajlw?yy?yX=(c(kf?F&45]N& w?~c;JuO> XG~>l8S:??-&LV&c*2(A?X[@?9&6M3m8PP#BQ)Z |Wy2FAt9^?w5 ,)mWxS$:{=:-. tiI3g->op)p:^V ?:8CB/?¢8®x9g@~x:=$q|( UYd~k"Y\w]by5f|i?zYUn@OInb2*hU+GIJ9'|P-YBhT&vUYPnC@]u0Z~oMbR\> uF(S?yl??k5z?knhTtP u3?3 G))@''#--nz~WM[[I?U;~MF!z`^W T>{w?up"ct Z|F?UwxA;G+ w>Wfjn100hsr ,6F.mOtsbJShY*v;@81|KVkf !?wDz=Y= endstream endobj 133 0 obj > endobj 134 0 obj > endobj 135 0 obj > stream LBKBKI+AdvP4A213B :d| AdvP4A213B$&/4P5%,.8@m=l 1f$0_O7}IxMlRrdo+L%q)Jxmq|Xq+|r"]wAv$Q?kr?jOÉ?grFnIoO& D&4??&D U5nf)$aa)$fn5U xommx|tn\;RlN]5?9klsH~( QwnjL ?i''7x© EAs?4]]4?7sBr'' endstream endobj 136 0 obj > endobj 137 0 obj > endobj 138 0 obj > /ExtGState > >> endobj 139 0 obj > endobj 140 0 obj > endobj 141 0 obj > stream xXnI}+FZiH=}$!U c{vaQ?dwO kenTS?;apQ:ee\BHjReE.>hYHL?i= X0HC-M>z?2!''apZRx}tT JE''|M.amLTZi?ttY5}!q.yj.(5wg¨&W?v>P???''oRFx:i4"7!|+u/N )''`B?S*TVZpTh+ ve ?2#AX5P~g y ?tPsS1.O8rL?a 0F#~2Ju?0(Gi(+CT4?QQhD5"!>!JnKe ] /Info 45 0 R >> startxref 146796 %%EOF

Table of Contents



1 In Vitro Evaluation of Metabolic Drug–Drug Interactions: Concepts and Practice (Albert P. Li).

1.1 Introduction.

1.2 Mechanisms of Adverse Drug–Drug Interactions.

1.2.1 Pharmacological Interactions.

1.2.2 Pharmacokinetic Interactions.

1.3 Drug Metabolism.

1.3.1 Phase I Oxidation.

1.3.2 Phase II Conjugation.

1.4 CYP Isoforms.

1.5 Human In Vitro Experimental Systems for Drug Metabolism.

1.5.1 Hepatocytes.

1.5.2 Liver Postmitochondrial Supernatant (PMS).

1.5.3 Human Liver Microsomes.

1.5.4 Recombinant P450 Isoforms (rCYP).

1.5.5 Cytosol.

1.6 Mechanisms of Metabolic Drug–Drug Interactions.

1.7 Mechanism-Based Approach for Evaluation of Drug–Drug Interaction Potential.

1.7.1 Metabolic Phenotyping.

1.7.2 Evaluation of Inhibitory Potential for Drug-Metabolizing Enzymes.

1.7.3 Induction Potential for Drug-Metabolizing Enzymes.

1.8 Experimental Approaches for In Vitro Evaluation of Drug–Drug Interaction Potential.

1.8.1 Study 1: Metabolic Phenotyping 1—Metabolite Identification.

1.8.2 Study 2: Metabolic Phenotyping 2—Identification of Major Metabolic Pathways.

1.8.3 Study 3: Metabolic Phenotyping 3—Identification of P450 Isoform Pathways (P450 Phenotyping).

1.8.4 Study 4: CYP Inhibitory Potential.

1.8.5 Study 5: Enzyme Induction Potential.

1.8.6 Study 6: In Vitro Empirical Drug–Drug Interactions.

1.9 Data Interpretation.

1.9.1 Pathway Evaluation.

1.9.2 P450 Inhibition.

1.9.3 P450 Induction.

1.10 Conclusion.


2 In Vitro Approaches to Anticipating Clinical Drug Interactions (Laurie P. Volak, David J. Greenblatt, and Lisa L. von Moltke).

2.1 In Vitro Systems for Human CYP450 Metabolism.

2.1.1 Incubation Buffer (pH and Ionic Strength).

2.1.2 MgCl2 and Cytochrome b5.

2.1.3 Nonspecific Binding.

2.1.4 Organic Solvents and Excipients.

2.2 Analysis of Data from In Vitro Systems.

2.2.1 Linear Transformation of Michaelis–Menten Equation (Lineweaver–Burk and Eadie–Hofstee).

2.2.2 Nonlinear Regression Analysis of Hyperbolic Kinetic Data.

2.2.3 Consideration of Non-Michaelis–Menten Kinetics.

2.3 Use of In Vitro Kinetic Data to Predict In Vivo Clearance.

2.3.1 Calculation of In Vitro (Predicted) Hepatic Clearance.

2.3.2 Comparison of In Vitro (Predicted) with In Vivo Hepatic Clearance.

2.4 Use of In Vitro Kinetic Data to Predict Drug–Drug Interactions.

2.4.1 Choice of Probe Substrates for Inhibition Studies.

2.4.2 Determining the Mechanism of CYP450 Inhibition.

2.4.3 Prediction of In Vivo Drug–Drug Inhibition Interactions from In Vitro Data.

2.5 Consideration of Non-CYP Enzymatic Systems.

2.5.1 Flavin-Containing Monooxygenase (FMO).

2.5.2 UDP-glucuronosyltransferase (UGT).

2.5.3 Sulfotransferase (SULT).

2.5.4 N-Acetyltransferase (NAT).

2.5.5 Methyltransferase.

2.5.6 Epoxidase Hydrolase.

2.5.7 Aldehyde Oxidase and Dehydrogenase.

2.5.8 Glutathione-S-transferase (GST).

2.6 Summary.

2.7 Acknowledgments.


3 Inhibition of Drug-Metabolizing Enzymes and Drug–Drug Interactions in Drug Discovery and Development (R. Scott Obach).

3.1 Introduction.

3.2 Laboratory Approaches Inhibiting Drug-Metabolizing Enzymes.

3.2.1 Analytical Method.

3.2.2 Determination of Linearity of Velocity.

3.2.3 Substrate Saturation Experiment.

3.2.4 Reversible Inhibition Experiments: Ki.

3.2.5 Reversible Inhibition Experiments: IC50.

3.3 Selection of Substrates for Inhibition Experiments in Drug Metabolism.

3.4 Inhibition of Drug-Metabolizing Enzymes in Drug Discovery and Development.

3.4.1 Inhibition Experiments in Early Drug Discovery.

3.4.2 Inhibition Experiments in Late Drug Discovery.

3.4.3 Inhibition Experiments During Drug Development.

3.5 Summary.


4 Mechanism-Based CYP Inhibition: Enzyme Kinetics, Assays, and Prediction of Human Drug–Drug Interactions (Magang Shou).

4.1 Kinetic Model for Mechanism-Based Inhibition.

4.2 Methodological Measurements of Kinetic Parameters.

4.3 Incubation.

4.3.1 CYP Isoform-Specific Assays.

4.3.2 General Incubation Procedure and Sample Preparation.

4.3.3 LC-MS–MS Analysis.

4.3.4 Data Analysis.

4.4 Prediction of Human DDIs from In Vitro MBI Data.

4.5 Acknowledgments.


5 Genomic Approaches To Drug–Drug Interactions (Yi Yang and Jeffrey F. Waring).

5.1 Introduction.

5.2 DNA Microarrays.

5.2.1 Array Platforms.

5.2.2 Gene Expression Profiling Using Microarray.

5.2.3 Genotyping Using Microarray.

5.3 Genomic Application Toward the Prediction of DDIs.

5.3.1 Gene Expression Profiling of Compound Mixtures.

5.3.2 Expression Profiling of DMEs and Transporters.

5.3.3 Identification of Gene Expression Patterns Indicative of DDIs.

5.4 Genomics Approach to Decipher the Molecular Basis of DDI: Nuclear Receptors.

5.5 Genomic Approaches to Address the Genetic Variability in DDIs.

5.6 Conclusion.


6 Transporters and Drug Interactions (Yoshihisa Shitara, Toshiharu Horie, and Yuichi Sugiyama)

6.1 Introduction.

6.2 Interactions Involving Liver Transporters.

6.2.1 Role of Transporters in the Biliary Excretion of Drugs.

6.2.2 Transporter-Mediated DDIs in the Process of Hepatobilary Excretion.

6.2.3 Transporters as a Determinant of Metabolic Rate.

6.3 Interactions in Intestine Transporters.

6.3.1 Role of Transporters in Intestinal Absorption.

6.3.2 Examples of Transporter-Mediated DDIs in the Process of Intestinal Absorption.

6.4 Drug Toxicity Involving Drug Transporters.

6.5 Drugs that Affect the Expression or Localization of Transporters.

6.6 Conclusion.


7 Transporter-Mediated Drug Interactions: Molecular Mechanisms and Clinical Implications (Jiunn H. Lin).

7.1 Introduction.

7.2 Tissue Distribution and Cellular Location of Transporters.

7.2.1 Small Intestine.

7.2.2 Liver.

7.2.3 Kidney.

7.2.4 Brain.

7.3 Molecular Mechanisms for Transporter Inhibition and Induction.

7.3.1 Inhibition of Transporters.

7.3.2 Induction of Transporters.

7.4 Drug Interactions Caused by Transporter Inhibition and Induction.

7.4.1 Direct Evidence.

7.4.2 Circumstantial Evidence.

7.5 Clinical Significance of Transporter-Mediated Drug Interactions.

7.6 Conclusion.


8 Recent Case Studies of Clinically Significant Drug–Drug Interactions and the Limits of In Vitro Prediction Methodology (René H. Levy, Isabelle Ragueneau-Majlessi, and Carol Collins).

8.1 Introduction.

8.2 Case Studies.

8.2.1 Interaction Between Repaglinide and Gemfibrozil þ Itraconazole.

8.2.2 Interaction Between Ramelteon and Fluvoxamine.


9 U.S. Regulatory Perspective: Drug–Drug Interactions (John Strong and Shiew-Mei Huang).

9.1 Introduction.

9.2 An Integrated Approach.

9.3 Methods for Evaluating Metabolic Clearance In Vitro.

9.3.1 CYP Reaction Phenotyping.

9.3.2 CYP Inhibition.

9.3.3 CYP Induction.

9.3.4 Other Metabolic Enzymes.

9.3.5 Transporters.

9.3.6 GLP Versus Non-GLP Studies.

9.4 In Vivo Approaches.

9.4.1 Study Design.

9.4.2 Data Analysis and Sample Size Consideration.

9.4.3 Classification of Inhibitors and Labeling Considerations.

9.4.4 Cocktail Approaches.

9.4.5 P-gp and Other Transporters.

9.5 Clinical Cases.

9.6 Regulatory Considerations.

9.7 Labeling.

9.8 Summary.


10 Herbal Drug Interactions—A Canadian Perspective (Brian C. Foster)

10.1 Introduction.

10.2 Interaction Risk Determination.

10.3 NHP Products.

10.3.1 NHP Characterization.

10.4 Disposition.

10.5 PD and PK interactions.

10.5.1 Choice of Substance Concentration Range.

10.5.2 Role of Animal Studies.

10.5.3 Human Clinical Studies.

10.6 Action.



Wiley Series in Drug Discovery and Development.